Core Insights - Conduit Pharmaceuticals has filed four new patent applications for its key assets AZD1656 and AZD5658, marking the first patent filings for AZD5658, which significantly expands the company's intellectual property portfolio [1][6] - The new patents are based on combinations of Conduit's lead assets with existing therapies, identified through AI-led analysis in collaboration with Sarborg Limited, enhancing the company's ability to generate novel, data-driven intellectual property [2][6] - The Chief Scientific Officer of Conduit Pharmaceuticals emphasized that these filings validate the progress made through the partnership with Sarborg, uncovering therapeutic combinations with substantial commercial potential [3] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [4] - The company utilizes a platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party licensing deals after successful clinical trials [4] - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, indicating a strong foundation for the company's innovative approach [4]

Core Insights - Conduit Pharmaceuticals has entered a joint development agreement with Manoira Corporation to evaluate its glucokinase activators AZD1656 and AZD5658 for veterinary applications, particularly in animal osteoarthritis [1][2][3] - The collaboration aims to generate preclinical data that will inform Conduit's human clinical programs while retaining full ownership of all related intellectual property [3][5][6] - This partnership opens new revenue streams in the growing $15 billion animal health market, projected to grow at a CAGR of 6.5% through 2027 [7][6] Company Strategy - The agreement highlights Conduit's commitment to innovative collaborations that maximize resource efficiency and pipeline potential [4] - By leveraging Manoira's expertise, Conduit aims to accelerate the development of AZD1656 and explore cross-species value through targeted programs [5][6] - The partnership is designed to enhance Conduit's competitive edge in glucokinase activator therapies and create a dual-track value proposition for shareholders [3][7] Financial Aspects - Manoira will fund all development activities, while Conduit will issue an upfront consideration of $500,000 through the issuance of 154,799 shares of common stock [8] - The collaboration is expected to reduce development timelines and costs for human clinical trials, enhancing the probability of success for AZD1656 in human indications [7][6] - The joint development agreement allows Conduit to retain exclusive rights and ownership of all new intellectual property related to AZD1656 and AZD5658 for human applications [5][4]

Core Insights - Conduit Pharmaceuticals has expanded its partnership with Sarborg to utilize advanced machine learning for analyzing clinical data from AstraZeneca-acquired assets, aiming to optimize development pathways and uncover new insights [1][2] Group 1: Partnership Details - The new agreement allows Sarborg to apply its proprietary machine learning algorithms to analyze Conduit's clinical and safety data, focusing on identifying missed insights and potential drug repurposing opportunities [2] - The collaboration includes a non-exclusive, non-transferable license for Conduit to access Sarborg's advanced algorithmic platform for six months, building on an existing Services Agreement [3] Group 2: Strategic Goals - The partnership aims to re-evaluate historical clinical trial data to identify specific patient subgroups that may have shown therapeutic benefits, which could refine Conduit's future clinical development strategy [2] - Dr. David Tapolczay, CEO of Conduit Pharmaceuticals, emphasized the commitment to leveraging data science to maximize the potential of their pipeline, particularly for key assets like AZD1656 [4] Group 3: Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets while utilizing AI and cybernetics [4] - The company aims for exits through third-party license deals following successful clinical trials, representing a departure from traditional pharma/biotech business models [4]

As filed with the Securities and Exchange Commission on September 4, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 (I.R.S. Employer Identification Number) 4995 Murphy Canyon Road, Suite 300 San Diego, CA 92134 (760) 471-8536 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) David Tapolczay Chief Executive Officer Conduit Pha ...

As filed with the Securities and Exchange Commission on September 4, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 CONDUIT PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 87-3272543 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 4995 Murph ...